Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

FC, Bidard; W, Jacot; N, Kiavue; S, Dureau; A, Kadi; E, Brain; T, Bachelot; H, Bourgeois; A, Gonçalves; S, Ladoire; H, Naman; F, Dalenc; J, Gligorov; M, Espié; G, Emile; JM, Ferrero; D, Loirat; S, Frank; L, Cabel; V, Diéras; L, Cayrefourcq; C, Simondi; F, Berger; C, Alix-Panabières; JY, Pierga

doi:10.1001/jamaoncol.2020.5660

Public

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

Shared by NobleBlocks on Jan 1, 2021 • 12:00 AM UTC

Authors:

Bidard FC

Jacot W

Kiavue N

Abstract

<h4>Importance</h4>The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!